Open access · US-GOV via ClinicalTrials.gov Clinical trial

Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone

Authors not listed

Ludwig Boltzmann Gesellschaft · 2007

Loss of proteostasis Human Randomized controlled trial

Abstract

The planned study has two purposes: 1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year. 2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-31 MST

Cite this

APA

Anonymous. (2007). Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone. <em>Ludwig Boltzmann Gesellschaft</em>. https://clinicaltrials.gov/study/NCT00533065

Vancouver

Anonymous. Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone. Ludwig Boltzmann Gesellschaft. 2007.

BibTeX

@misc{anon2007Effect, title = {Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone}, author = {Anonymous}, journal = {Ludwig Boltzmann Gesellschaft}, year = {2007}, }